Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total

Status Completed

Clinical Trial Summary

You are being asked to take part in this research study because you are scheduled to have total hip replacement (arthroplasty) surgery. The goal of this study is to evaluate the effectiveness of the drug, epsilon Aminocaproic Acid (EACA), in decreasing the need for patients to receive blood after surgery. Currently, EACA is approved by the Federal Drug Administration (FDA) to treat a patient who is bleeding. The investigators plan to use EACA to prevent bleeding during and after surgery; use of this drug as a means of preventing bleeding is not currently approved by the FDA.

Clinical Trial Description

The goal of this prospective randomized study is to evaluate the effectiveness of a drug, epsilon aminocaproic acid (EACA), in reducing the frequency of postoperative blood transfusion following primary total hip arthroplasty. In our institution, up to 40% of patients with a preoperative of 13.5 g/dl or less undergoing total hip arthroplasty will require a blood transfusion. Fibrinolytic drugs such as EACA and tranexamic acid (TA) have been shown to decrease blood loss during surgery and decrease the likelihood of blood transfusion during postoperative hospitalization.. Both drugs decrease the body's ability to break down a blood clot, thus pushing the balance of blood clot formation and breakdown towards clot formation. This mechanism can decrease the amount of blood loss during and after a surgical procedure. The haemostatic effect of EACA has been investigated in multiple studies with the majority showing a positive effect on postoperative hemoglobin levels and decreased blood transfusion rates. Though several studies exist revealing the effective and safe use of perioperative TA, a similar drug to EACA, there is a paucity of information on the use of EACA in total joint arthroplasty. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01391182
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Completed
Phase	N/A
Start date	July 2011
Completion date	January 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04657926` - A Trial of APPA in the Treatment of Knee Osteoarthritis	Phase 2
Completed	`NCT02536833` - A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects	Phase 2
Completed	`NCT03014037` - Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration	N/A
Recruiting	`NCT05937542` - A Qualitative Investigation of CLEAT Participants
Completed	`NCT03644615` - A Mindfulness Program (MBSR) in the Management of Symptomatic Hip and Knee Osteoarthritis	N/A
Recruiting	`NCT06061367` - Muscles Strength and Gait Parameteres After TKA
Withdrawn	`NCT04976972` - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation	N/A
Completed	`NCT05496205` - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers	Phase 1
Completed	`NCT03850665` - Comparison of Functional Outcome in Patients After Hip Arthroplasty Depending on Surgical Approach	N/A
Completed	`NCT02826902` - Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial	N/A
Completed	`NCT04402502` - Dynamic 4DCT to Examine Wrist Carpal Mechanics	N/A
Completed	`NCT02923700` - Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial	Phase 4
Completed	`NCT04564053` - Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants	Phase 1
Completed	`NCT05070871` - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women	N/A
Not yet recruiting	`NCT05036174` - Diphenhydramine Ointment for Knee Osteoarthritis	N/A
Recruiting	`NCT02912429` - Onlay vs. Inlay Patellofemoral Arthroplasty	N/A
Recruiting	`NCT02666443` - Low Dose Dexamethasone in Supraclavicular Blocks	N/A
Active, not recruiting	`NCT02723929` - Effects of tDCS and tUS on Pain Perception in OA of the Knee
Terminated	`NCT02820766` - Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting	N/A
Withdrawn	`NCT02921594` - Kinematic Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms